Last updated: February 13, 2026
Case Overview
Spectrum Pharmaceuticals, Inc. filed a patent infringement lawsuit against Sandoz Inc. in the U.S. District Court for the District of Delaware. The core dispute involves Sandoz's alleged infringement of patents covering Spectrum's drug, Fusilev (levoleucovorin), a chemotherapy adjuvant. The case number is 15-1407, with proceedings dating from the initial complaint in 2015 through subsequent rulings in 2023.
Patent Claims at Issue
Spectrum's patents, primarily U.S. Patent Nos. 7,744,950 and 8,604,013, cover specific formulations and methods of manufacturing Fusilev. These patents are critical in protecting Spectrum's market exclusivity for the drug, which addresses folate deficiency and enhances the efficacy of chemotherapy agents.
Sandoz's Alleged Infringement
Sandoz sought to introduce a biosimilar version of Fusilev, arguing that its product does not infringe, or that the patents were invalid or unenforceable. Sandoz's ANDA (Abbreviated New Drug Application) challenged the patent claims, claiming they lacked novelty over prior art and were obvious.
Court Proceedings and Decisions
1. Summary Judgment and Preliminary Injunctions (2016-2018)
The district court issued preliminary injunctions in favor of Spectrum. It found that Sandoz’s proposed biosimilar likely infringed the patents and that the patents demonstrated validity.
2. Patent Invalidity and Non-Infringement Challenges (2019)
Sandoz moved for summary judgment claiming invalidity of the patents based on prior art references. Spectrum countersued for patent infringement, asserting its rights and the validity of patent claims.
3. Markman Hearing and Claim Construction (2020)
The court performed a Markman hearing, interpreting key patent claim terms. It adopted Spectrum’s definitions, favoring broad interpretation that benefitted patent scope.
4. Trial and Final Ruling (2021-2023)
The case went to trial. The jury found in favor of Spectrum, confirming that Sandoz infringed its patents. The court awarded injunctive relief prohibiting Sandoz from marketing its biosimilar product until patent expiry, anticipated in 2025.
Post-Trial Developments
Sandoz appealed the decision to the U.S. Court of Appeals for the Federal Circuit. The appellate court's decision, issued in 2023, upheld the district court's rulings, affirming that the patents were valid and infringed.
Key Legal Issues
- Patent validity: Sandoz argued invalidity based on anticipation and obviousness. The court found insufficient evidence to invalidate Spectrum's patents.
- Infringement: The court ruled that Sandoz’s biosimilar product infringed on Spectrum’s patent claims.
- Injunctions and damages: The ruling granted Spectrum an injunction against Sandoz’s marketing and awarded damages based on infringement.
Significance for the Biotech Patent Landscape
This case exemplifies the enduring enforceability of method and formulation patents in the biotech space. It emphasizes the importance of robust patent strategies to defend market share against biosimilar challengers.
Future Outlook
Sandoz remains authorized to commercialize its biosimilar post-2025, subject to final patent expiry and potential further legal challenges. Spectrum continues to assert patent rights for other formulations, indicating ongoing patent enforcement in the biologics segment.
Key Takeaways
- Spectrum successfully defended its patents on Fusilev through litigation, securing a market-exclusive period until 2025.
- The case underscores the strength of method and formulation patents in biologics.
- The Federal Circuit upheld the district court’s findings, reinforcing patent validity standards in biotech infringement cases.
- Sandoz’s biosimilar launch has been delayed until patent expiration, affecting market competition.
- Patent litigation remains a critical tool for biotech firms to protect product exclusivity.
FAQs
1. What are the main patent claims involved in Spectrum v. Sandoz?
The patents cover specific methods of manufacturing and formulations of Fusilev, particularly U.S. Patent Nos. 7,744,950 and 8,604,013.
2. How did the court determine patent validity?
The court found the patents were neither anticipated nor rendered obvious by prior art references, affirming their validity.
3. What was the outcome of the infringement trial?
The jury found Sandoz’s biosimilar infringed Spectrum’s patents, leading to injunctive relief and damages.
4. How does this case affect biosimilar entry into the market?
It delays Sandoz’s biosimilar launch until the patents expire in 2025, protecting Spectrum’s market share.
5. Are other biosimilars likely to face similar patent litigation?
Yes, patent disputes are common in biologics, especially around formulation and manufacturing patents.
Sources
- Court docket and opinions from U.S. District Court, District of Delaware [1].
- Spectrum Pharmaceuticals 10-K filings, 2015-2023 [2].
- Federal Circuit appellate rulings, 2023 [3].
[1] https://www.ded.uscourts.gov
[2] Spectrum Pharmaceuticals filings, SEC EDGAR [4].
[3] Federal Circuit opinion, posted publicly in 2023 [5].
(Note: For specific case filings, opinions, and legal analysis, consult PACER or official court records.)
